Epygenix Therapeutics Announces Appointment of G. Michael Landis as Chief Financial OfficerMar 23, 2022 | News
Health Canada Issues No Objection Letter to Initiate the ELEGANSE Trial With EPX-100 to Treat Lennox-Gastaut SyndromeFeb 16, 2022 | News
Epygenix Therapeutics Announces FDA Acceptance of IND to Initiate a Clinical Trial of EPX-100 to Treat Lennox-Gastaut SyndromeAug 30, 2021 | News
Health Canada Grants No Objection Letter to Epygenix Therapeutics to Proceed With ARGUS Trial for the Treatment of Dravet SyndromeAug 2, 2021 | News
Epygenix Therapeutics Receives Orphan Medicinal Product Designation in Europe With EPX-200 for the Treatment of Patients With Dravet SyndromeAug 2, 2021 | News
